再激活氧化型可溶性鸟苷酸环化酶作为延缓钙化性主动脉瓣狭窄进展的新治疗策略:临床前与随机临床试验评估安全性和有效性
研究在人体瓣膜组织、细胞和小鼠中证实钙化性主动脉瓣狭窄存在sGC信号受损,ataciguat可增强sGC信号并减少BMP2信号、减缓小鼠瓣膜钙化进展。随后开展的I期和II期随机安慰剂对照试验显示,ataciguat 2周安全耐受,6个月可减缓中重度FCAVS患者主动脉瓣钙化进展并趋向减缓瓣膜和心室功能障碍进展。
要点
- FCAVS患者瓣膜组织存在sGC信号显著丢失,尽管sGC亚基表达上调。
- Ataciguat在临床前模型中增强sGC信号、抑制BMP信号并减缓瓣膜钙化与功能障碍进展。
- II期试验中ataciguat 6个月减缓主动脉瓣钙化进展,并趋向减缓瓣膜和心室功能障碍进展。
核心结论
- 靶向恢复病变/失活型sGC(可溶性鸟苷酸环化酶)对钙化性主动脉瓣狭窄具有治疗潜力。
研究设计与样本
- 临床前研究:使用定量实时逆转录聚合酶链反应、Western印迹和免疫组化,在切除的人主动脉瓣组织、主动脉瓣间质细胞和小鼠主动脉瓣中表征sGC信号及ataciguat对一氧化氮、钙化和纤维化相关信号级联的生物学效应。
- 随机安慰剂对照I期试验(14天安全性/耐受性)和II期试验(6个月有效性),纳入中度主动脉瓣狭窄患者。
主要发现
- 切除的人瓣膜组织中sGC信号显著丢失,尽管sGC亚基上调。
- 体外实验中ataciguat增加主动脉瓣间质细胞sGC信号并减少BMP2(骨形态发生蛋白2)信号。
- 已建立FCAVS的小鼠中,ataciguat减弱BMP信号并减缓瓣膜钙化和功能障碍进展。
- I期随机安慰剂对照试验中,ataciguat治疗2周在中度FCAVS患者中安全且耐受良好(NCT02049203)。
- II期随机安慰剂对照试验中,ataciguat治疗6个月减缓中度FCAVS患者主动脉瓣钙化进展,并趋向减缓瓣膜和心室功能障碍进展(NCT02481258)。
临床怎么用
- Ataciguat 2周在中度FCAVS患者中安全耐受,6个月可减缓主动脉瓣钙化进展。
- ataciguat对瓣膜和心室功能障碍进展的减缓作用仅为趋向性,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS. METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis. RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS (https://www.clinicaltrials.gov; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS (https://www.clinicaltrials.gov; Unique identifier: NCT02481258). CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02481258.
引用
- Zhang B, Enriquez-Sarano M, Schaff HV, et al. Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow Progression of Calcific Aortic Valve Stenosis: Preclinical and Randomized Clinical Trials to Assess Safety and Efficacy. Circulation. 2025. PMID: 39989354. doi:10.1161/CIRCULATIONAHA.123.066523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。